4 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Inotrem: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model Additional biopsies and blood samples - Inflammatory Bowel Diseases | Recruiting | Inotrem | 40 | 2023-01-31 | 2025-02-27 | |
| Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis Blood sampling - Radiation Toxicity, Fibrosis | Not applicable | Unknown | Centre Francois Baclesse, Luxembourg | 20 | 2022-04-01 | 2022-06-23 |
| TREM-1 Pathway Activation in COVID-19 blood sampling - Covid19 | Completed | Central Hospital, Nancy, France | 830 | 2020-10-01 | 2022-03-22 | |
| Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support nangibotide, placebo - COVID19 | Phase 2 | Completed | Inotrem | 220 | 2020-09-23 | 2023-05-03 |
| Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock nangibotide low dose, nangibotide high dose, placebo - Shock, Septic | Phase 2 | Active not recruiting | Inotrem | 355 | 2019-11-13 | 2023-04-11 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock Nangibotide 0.3 mg/kg, Placebo, Nangibotide 1 mg/kg - Shock, Septic | Phase 2 | Completed | Inotrem | 50 | 2017-07-03 | 2024-10-08 |
| Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects nangibotide, Placebo - Healthy Subjects | Phase 1 | Completed | Inotrem | 27 | 2016-04-01 | 2025-02-10 |
COVID-19 (2) · Shock, Septic (2) · Breast Neoplasms (1) · Fibrosis (1) · Inflammatory Bowel Diseases (1) · Radiation Injuries (1) · Sepsis (1)
nangibotide (4) · Blood Specimen Collection (3)
France (5) · Belgium (3) · Spain (2) · Denmark (1) · Finland (1) · Ireland (1) · Italy (1) · Luxembourg (1) · Netherlands (1) · United Kingdom (1)
PMID 29885068, PMID 34233965, PMID 37269870, PMID 37350989
2018 (1)